Mycenax Biotech Inc.


Please enter the company code as 4726 Go to Link
Company profile

About Mycenax

Established in 2001, Mycenax Biotech Inc. (Mycenax) is a company with biopharmaceutical development and manufacturing platform. We dedicate to using single-use technology in full line and pursuing to provide the cost-effective, fast speed and international quality complied CMC foundation for CDMO service.
Mycenax owns the first USFDA Master File registered plant in Taiwan and obtains Taiwan PIC/S GMP certification from health and welfare department in Taiwan. In addition, Mycenax's biological drug development follows ICH guidelines and meets the requirements of FDA, EMA, and AFM of Japan. Mycenax's protein-drug manufacturing process uses single-use technology, with a maximum bioreactor of 2000 liters and has accumulated more than 18 years of experience in the development of biopharmaceuticals.
read more

Business advantage

News and Events News

more news


Mycenax won the First Prize of Merck’s Advance Biotech Grant Program

 Merck, a science and technology company, announced the winners of its Advance Biotech Grant program in Taiwan. The first prize went to Mycenax. Applicants from biotech companies in Taiwan were asked to describe their projects such as the medical needs they solved and process development challenges they faced. In support of the growing biotech ecosystem, grant recipients received the products and process development support that are equivalent to NT$16,000,000. Mycenex won the NT$4,600,000 with the honor of the first prize winner.Merck selected the winners based on the expertise with the scientific and societal merit of therapy in development and process challenges. Therefore, with this glory and compliment, Mycenax will keep providing our client state of the art technology to meet all their demands and be their flexible and professional partner.   “Mycenax is honored to be selected as the first place in the Advance Biotech Grant,” said Leo Su, Vice president of Mycenax. “Under the resources provided by this grant, we intend to optimize a robust and scalable continuous process that can link the process of upstream and downstream more smoothly.” Mycenax is the first Taiwan leading pharmaceutical company with one-stop biopharmaceutical capabilities and technology development platforms. In recent years, Mycenax has continuously strengthened the CDMO research and development energy to assisted European, American, and Japanese customers to develop protein drugs with single-use technology for over ten years. Furthermore, Mycenax has engaged in a partnership with Dutch business developers to advance the continuous process in recent years and become the world’s first new drug developer who utilizes the process to pass clinical applications. Mycenax has commissioned development projects to internationally renowned pharmaceutical companies and has carried out phase I clinical trial and phase III clinical trial, indicating that Mycenax is highly recognized by the capability and technologies.


Mycenax participates in the Biointernational convention in Philadelphia to actively expand business opportunity

Mycenax participates in the BIO International Convention, the world's largest biotechnology industry exhibition, and actively expands its business.The BIO International Convention is the world's largest annual biotech event, held in major cities in the United States. This year's convention was held in Philadelphia, USA from June 3rd to 6th. Mycenax participated in an exhibition group consisting of Taiwanese officials and industry and exhibited at the Taiwan Pavilion to introduce its one-stop CDMO service for biopharmaceutical research and development.Since its establishment, Mycenax has developed its own biosimilar products and accumulated a considerable number of experience in commissioned services. It has rich experience in product development, production, and quality management, and can provide a series of services with fast service, high quality, and reliability. From research and development strategies and execution plans to providing bio-medical development platforms, we provide listed products that meet customer requirements for regulatory and quality requirements.Through the docking negotiation of this exhibition, we will continue to contact many potential customers, show our accumulated experience and advantages, and create business opportunities worldwide.


Mycenax cooperates with Norwegian Vectron Biosolutions AS to create a high-volume microbiology platform for global CDMO

Mycenax Biotech Inc., leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Vectron Biosolutions AS, a Norway-based service provider focused on developing broad-host-range vector technology for industrial production of recombinant proteins, today announced they have signed a cooperation agreement. Under the terms of the agreement, Vectron and Mycenax will join forces to offer the industry a superior and complete solution for industrial microbial production of therapeutic proteins. Vectron will use its proprietary VB Expression technology platform, to develop robust and cost-efficient microbial strains for production of therapeutic proteins. The microbial strains will be transferred to Mycenax’ state-of-the-art biopharmaceutical manufacturing facility for the production of pre-clinical and clinical materials. The combined services of Mycenax and Vectron fulfill the needs of CDMO customers who require protein production with large scale, low cost, and high quality.  In the past, Mycenax has successfully established various innovative biopharmaceutical manufacturing technologies, both through its own R&D capability and collaboration with international organizations. The goal is to support customers in developing and manufacturing highly competitive biopharmaceutical products. Pei-Jiun Chen, President of Mycenax, said: “Microbial strains have the advantages of low cost, easy scale-up, and short production cycle. Therefore, many biotech companies choose microbial systems to produce their products. By collaborating with Vectron, Mycenax can offer a better total solution for customers choosing microbial systems” The product yield plays a critical role for the production of recombinant proteins. The average protein production of a microbial cell line on the market is about 1-2 g/L. In contrast, Vectron's proprietary technology platform can achieve stable microbial strains with yields of up to 50 g/L. This increase in productivity significantly improves the COG and hence the competitiveness of the product. Vectron is based on the knowledge gained over decades of academic research and development by Professor Svein Valla and Dr. Trond Erik Aune at the Department of Biotechnology at the University of Science and Technology in Trondheim, Norway. Professor Valla was a world-leading expert on gene expression in bacteria and plasmid design and he developed a novel expression vector system by combining features of the RK2 plasmid with the promoter system from the pWW0 plasmid. Vectron is able to design and identify the most appropriate microbial expression vector for maximized protein yield. Dr. Trond Erik Aune, Chief Executive Officer of Vectron, said: “Through the cooperation with Mycenax, we can extend the services to our customers from strain development to complete CMC development and CDMO services. This is a win-win situation for Vectron, Mycenax, and our customers.” The combined services of Mycenax and Vectron target international biopharmaceutical companies developing novel biological drugs as well as biosimilar developers that want to reduce their production costs. About Mycenax Biotech Inc. Mycenax Biotech Inc. offers state-of-the-art biopharmaceutical development and manufacturing services for mammalian and microbial systems. For more information, please visit: About Vectron Biosolutions AS Vectron Biosolutions AS supplies the life science industries with superior technologies and solutions for robust and cost-efficient production of recombinant proteins in E. coli and other bacteria. For more information, please visit   


Pearl Fong, our vice president, was invited to have a speech in SNU BIO-MAX International Conference 2018.

It is our pleasure that Pearl Fong, our vice president, was invited to have a speech in SNU BIO-MAX International Conference 2018 which is held at Seoul National University on November 27, 2018. In the speech, Pearl shared the experience that Mycenax has the unique platform ‘’MBIFastTM’’ which could shorten the process development timeline and improve the product quality for the therapeutic monoclonal antibody.   Mentioned in the speech, Mycenax’s efforts for our customers for continuous innovation never cease, as we always seek “new evolution” of technologies. “What do drug developers care most when it comes to production processes? “ Pearl asked. The answers are simple – time, quality, and cost – and our solutions make addressing those needs easier than ever!In the conference, we provided the insight of the market trend and the R&D technology to the experts in Korea. We not only increase our brand awareness worldwide but also show our strengths that meet international standards and regulations.